#drug-pricing

A report from STAT says ultra-low doses may help costly cancer treatments reach more patients in poorer countries, putting affordability at the center of oncology access.

The Supreme Court rejected a challenge to Medicare drug price negotiation, a move that could make the pharmaceutical industry’s remaining lawsuits harder to win.

Amgen and AbbVie say the first negotiated Medicare drug prices under the Inflation Reduction Act are now affecting business results, offering an early view into how the policy is changing the market.

Novartis chief executive Vas Narasimhan says the company is very disappointed by Germany’s plan to cut more than €60 billion in healthcare costs, setting up an early clash over the consequences for drug sales and market

AbbVie has sued the federal government over how it interprets the word “patient” in the 340B drug discount program, opening a new front in one of the most consequential pricing disputes in U.S. healthcare.

A study found that Medicare patients spent less on insulin after a $35 monthly cap took effect in 2023, with evidence that more patients adhered to treatment.

Pharmaceutical companies and patient groups are pushing to exempt orphan drugs from potential Colorado pricing limits, opening a new front in the broader debate over rare-disease treatments and affordability.

A STAT opinion piece argues that subscription-style pricing could broaden access to the HIV prevention drug lenacapavir while helping manage costs, highlighting the growing policy debate around breakthrough medicines.

Biopharma companies are restructuring international licensing agreements to reduce their exposure to Most Favored Nation pricing rules, which link US drug prices to the lowest prices paid in other countries.

Novo Nordisk and Hims & Hers have ended their legal battle with a partnership that could reshape the booming compounded GLP-1 drug market and limit cheaper alternatives.